









市場行情
/
股票
/
nasdaq-cort
/

Corcept Therapeutics Inc

CORT

80.280USD

+2.570+3.31%

收盤 11/25, 16:00（美東）報價延遲15分鐘

8.44B總市值

79.53本益比TTM



Corcept Therapeutics Inc

80.280

+2.570+3.31%

概覽公司財務分析

概覽

公司

財務

分析

關於 Corcept Therapeutics Inc 公司

Corcept Therapeutics Incorporated 是一家商業階段公司，致力於發現和開發通過調節激素皮質醇作用來治療嚴重內分泌、腫瘤、代謝和神經系統疾病的藥物。該公司通過發現、開發和商業化醫藥產品部門開展業務。該公司已在美國銷售 Korlym（米非司酮），用於治療患有庫欣綜合徵的患者。該公司的選擇性皮質醇調節劑產品組合由四個系列組成，共計約 1,000 種化合物。其選擇性皮質醇調節劑產品組合包括 relacorilant、exicorilant、dazucorilant 和 miricorilant。Korlyms 的活性成分米非司酮可減少過量皮質醇與 GR 的結合，它可以調節皮質醇異常水平和釋放模式的影響，而不會損害皮質醇的健康功能和節律。

Corcept Therapeutics Inc簡介



公司代碼CORT

公司名稱Corcept Therapeutics Inc

上市日期Apr 15, 2004

CEODr. Joseph K. Belanoff, M.D.

員工數量500

證券類型Ordinary Share

年結日Apr 15

公司地址101 Redwood Shores Parkway

城市REDWOOD CITY

上市交易所NASDAQ Capital Market Consolidated

國家United States of America

郵編94065

電話16506888803

網址https://www.corcept.com/

公司代碼CORT

上市日期Apr 15, 2004

CEODr. Joseph K. Belanoff, M.D.

Corcept Therapeutics Inc公司高管



名稱

名稱/職務

職務

持股

持股變動

Dr. Joseph K. Belanoff, M.D.

President, Chief Executive Officer, Co-Founder, Director

2.98M

-0.02%

Mr. James N. (Jim) Wilson

Independent Chairman of the Board

2.35M

+5.82%

Mr. David L. Mahoney

Independent Director

1.26M

Dr. Hazel Hunt, Ph.D.

Chief Scientific Officer

183.41K

+54.67%

Mr. Sean Maduck

President - Corcept Endocrinology

97.60K

Mr. Gary Charles (Charlie) Robb

Chief Business Officer, Secretary

36.03K

+0.69%

Mr. Atabak Mokari

Chief Financial Officer, Treasurer

14.32K

+1.82%

Mr. Joseph Douglas Lyon

Chief Accounting and Technology Officer

10.28K

Mr. William Guyer, Pharm.D.

Chief Development Officer

5.29K

Mr. Gregg Huber Alton, J.D.

Independent Director

名稱

名稱/職務

職務

持股

持股變動

Dr. Joseph K. Belanoff, M.D.

President, Chief Executive Officer, Co-Founder, Director

2.98M

-0.02%

Mr. James N. (Jim) Wilson

Independent Chairman of the Board

2.35M

+5.82%

Mr. David L. Mahoney

Independent Director

1.26M

Dr. Hazel Hunt, Ph.D.

Chief Scientific Officer

183.41K

+54.67%

Mr. Sean Maduck

President - Corcept Endocrinology

97.60K

Mr. Gary Charles (Charlie) Robb

Chief Business Officer, Secretary

36.03K

+0.69%

收入明細

由於公司未披露，未能獲取相關數據

由於公司未披露，未能獲取相關數據

業務

地區

由於公司未披露，未能獲取相關數據

股東統計

更新時間: 11月16日週日

持股股東

股東類型

持股股東

佔比

BlackRock Institutional Trust Company, N.A.

10.39%

The Vanguard Group, Inc.

9.05%

Ingalls & Snyder LLC (Asset Management)

7.32%

Renaissance Technologies LLC

5.79%

Baker (George Leonard Jr.)

5.05%

其他

62.41%

持股股東

佔比

BlackRock Institutional Trust Company, N.A.

10.39%

The Vanguard Group, Inc.

9.05%

Ingalls & Snyder LLC (Asset Management)

7.32%

Renaissance Technologies LLC

5.79%

Baker (George Leonard Jr.)

5.05%

其他

62.41%

股東類型

持股股東

佔比

Investment Advisor

41.89%

Investment Advisor/Hedge Fund

22.83%

Individual Investor

11.63%

Hedge Fund

7.39%

Pension Fund

1.39%

Sovereign Wealth Fund

0.96%

Research Firm

0.74%

Bank and Trust

0.43%

Family Office

0.06%

其他

12.68%

機構持股



更新時間: 10月1日週三

報告期間

機構數

持股數

持股佔比

持股變動

2025Q3

791

81.34M

77.33%

-10.47M

2025Q2

740

96.93M

91.97%

-8.00M

2025Q1

746

97.45M

92.10%

-9.12M

2024Q4

673

98.29M

93.20%

-10.89M

2024Q3

625

101.82M

97.42%

-10.51M

2024Q2

589

103.22M

99.09%

-12.69M

2024Q1

582

107.51M

103.94%

+2.98M

2023Q4

555

98.31M

95.40%

-4.22M

2023Q3

540

96.45M

94.14%

-5.68M

2023Q2

523

94.35M

92.83%

-12.18M

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

BlackRock Institutional Trust Company, N.A.

11.31M

10.74%

-1.71M

-13.12%

Jun 30, 2025

The Vanguard Group, Inc.

9.66M

9.17%

-301.38K

-3.03%

Jun 30, 2025

Ingalls & Snyder LLC (Asset Management)

7.72M

7.33%

-19.66K

-0.25%

Jun 30, 2025

Renaissance Technologies LLC

6.27M

5.95%

+123.37K

+2.01%

Jun 30, 2025

Baker (George Leonard Jr.)

5.31M

5.04%

Apr 17, 2025

Parallel Advisors, LLC

3.87M

3.67%

-101.29K

-2.55%

Jun 30, 2025

Belanoff (Joseph K)

2.98M

2.83%

-615.00

-0.02%

Jul 17, 2025

State Street Investment Management (US)

2.97M

2.82%

-434.35K

-12.77%

Jun 30, 2025

Wilson (James N)

2.35M

2.23%

+129.14K

+5.82%

Apr 17, 2025

Fidelity Management & Research Company LLC

1.36M

1.29%

-121.95K

-8.25%

Jun 30, 2025

持股ETF



更新時間: 11月6日週四

機構名稱

佔比

Invesco S&P SmallCap Health Care ETF

4.95%

Formidable ETF

4.17%

First Trust NYSE Arca Biotechnology Index Fund

3.59%

Invesco Pharmaceuticals ETF

3.19%

iShares U.S. Pharmaceuticals ETF

2.88%

SPDR S&P Pharmaceuticals ETF

2.79%

Alger Russell Innovation ETF

2.28%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

2.09%

Fidelity Stocks for Inflation ETF

1.77%

Invesco S&P SmallCap 600 Pure Growth ETF

1.76%

Invesco S&P SmallCap Health Care ETF

佔比4.95%

Formidable ETF

佔比4.17%

First Trust NYSE Arca Biotechnology Index Fund

佔比3.59%

Invesco Pharmaceuticals ETF

佔比3.19%

iShares U.S. Pharmaceuticals ETF

佔比2.88%

SPDR S&P Pharmaceuticals ETF

佔比2.79%

Alger Russell Innovation ETF

佔比2.28%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

佔比2.09%

Fidelity Stocks for Inflation ETF

佔比1.77%

Invesco S&P SmallCap 600 Pure Growth ETF

佔比1.76%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

類型

比率

暫無數據

公告日期

類型

比率

暫無數據

常見問題

Corcept Therapeutics Inc的前五大股東是誰？



Corcept Therapeutics Inc的前五大股東如下：
BlackRock Institutional Trust Company, N.A.
持有股份：11.31M
佔總股份比例：10.74%。
The Vanguard Group, Inc.
持有股份：9.66M
佔總股份比例：9.17%。
Ingalls & Snyder LLC (Asset Management)
持有股份：7.72M
佔總股份比例：7.33%。
Renaissance Technologies LLC
持有股份：6.27M
佔總股份比例：5.95%。
Baker (George Leonard Jr.)
持有股份：5.31M
佔總股份比例：5.04%。